Summary of the 2013 American lipid guidelines

Strengths of this protocol include a more evidence-based approach and a move away from specific cholesterol targets, a practice never supported by clinical trial evidence. Concerns include extensive industry connections among half of the guideline panel, a calculator that does not reliably predict risk, a low 10-year risk cut-off (7.5 per cent) for treatment with a statin, and a failure to clearly communicate the absolute risks and harms of treatment, especially for those at low risk.

Summary of the 2013 American lipid guidelines

Add yours ↓
Web design and marketing agency Leamington Spa